Trius Therapeutics (TSRX) Prices $6.3M Stock Offering at $4.75/Share

January 18, 2013 8:02 AM EST Send to a Friend
Get Alerts TSRX Hot Sheet
Trade TSRX Now!
Join SI Premium – FREE
Trius Therapeutics, Inc. (Nasdaq: TSRX) today announced the pricing of an underwritten public offering of 6,300,000 shares of its common stock at a price to the public of $4.75 per share. The gross proceeds to Trius from this offering are expected to be approximately $29,925,000 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering is expected to close on or about January 24, 2013, subject to customary closing conditions.

Citigroup and Leerink Swann are acting as joint book-running managers and Baird is acting as a co-lead manager in the offering. Trius has granted the underwriters a 30-day option to purchase up to an aggregate of 945,000 additional shares of common stock. Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial, preclinical and other research and development expenses, capital expenditures, working capital and general and administrative expenses.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Equity Offerings

Related Entities

Citi, Robert W Baird

Add Your Comment